{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:07:28Z","timestamp":1790168848794,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.esmogo.2024.100050","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T18:37:30Z","timestamp":1713379050000},"page":"100050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experience"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-8383","authenticated-orcid":false,"given":"S.","family":"Takei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-1487","authenticated-orcid":false,"given":"S.","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-9212","authenticated-orcid":false,"given":"M.","family":"Yura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-0189","authenticated-orcid":false,"given":"N.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-8733","authenticated-orcid":false,"given":"T.","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2024.100050_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2024.100050_bib2","series-title":"Japanese Gastric Cancer Treatment Guidelines 2021","year":"2021"},{"issue":"suppl 5","key":"10.1016\/j.esmogo.2024.100050_bib4","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmogo.2024.100050_bib6","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100050_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100050_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"10184","key":"10.1016\/j.esmogo.2024.100050_bib9","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100050_bib10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"33","key":"10.1016\/j.esmogo.2024.100050_bib11","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100050_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmogo.2024.100050_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial","volume":"37","author":"Yoshida","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100050_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.esmogo.2024.100050_bib15","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100050_bib16","doi-asserted-by":"crossref","first-page":"S1318","DOI":"10.1016\/j.annonc.2023.10.079","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2024.100050_bib17","article-title":"Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial","volume":"41","author":"Kang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmogo.2024.100050_bib18","article-title":"Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial)","volume":"35","author":"Tokunaga","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100050_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100050_bib20","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100050_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100050_bib22","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.esmogo.2024.100050_bib23","series-title":"Japanese Classification of Gastric Carcinoma","year":"2017"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100050_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","year":"2011","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100050_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10147-011-0349-5","article-title":"Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials","volume":"18","author":"Yano","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100050_bib26","doi-asserted-by":"crossref","first-page":"v300","DOI":"10.1093\/annonc\/mdz247.103","article-title":"777P Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen","volume":"30","author":"Crampton","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100050_bib27","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100050_bib28","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival : an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100050_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","article-title":"Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study","volume":"270","author":"Choi","year":"2019","journal-title":"Ann Surg"},{"issue":"35","key":"10.1016\/j.esmogo.2024.100050_bib30","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10294","key":"10.1016\/j.esmogo.2024.100050_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:24:35Z","timestamp":1762651475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"alternative-id":["S2949819824000116"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100050","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2443665\/v1","asserted-by":"object"}]},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experience","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100050"}}